Articles tagged ‘’

A recently published study finds that heart failure patients willing to take part in clinical trials have a better prognosis than those unwilling to do so.

A conference at Heart House on 5 November aims to raise awareness of the need for gender-specific research and treatment. Heart disease and stroke are the leading causes of death for women worldwide, killing more than 8.6 million, more than the total number who die from cancer, tuberculosis, HIV/AIDS and malaria combined.

The most recent course was held on 7-8 September 2009. A small amount of pre-course reading is provided by the course organiser along with a very entertaining (and educational!) web link to a tutorial on eye movements. The first day of the course covered anatomy and physiology, investigations and differential diagnoses and concluded with a very interactive session on balance and balance rehab.

The theme of this year’s World Stroke Day on 29th October is “What can I do?”. As the World Stroke Organization says, everyone can do something: learn to recognise symptoms and take action, learn to recognise the risk factors and take action.

The European Society of Cardiology (ESC) has recently commented on recent media reports that France is preparing to authorise the sale of cigarettes on the internet, to conform to European rights. Although Budget Minister Eric Woerth denies that this is the intention, the news is disappointing given the drop in heart attack rates following last year’s smoking ban.

Over one thousand delegates attended the Heart Rhythm Congress (HRC) 2009, held recently in Birmingham. Reflecting the increasing interest in the fast moving field of pacing, devices and all aspects of heart rhythm control, the congress caters for leading cardiac electrophysiology clinicians, cardiology trainees, supporting health professionals and also included presentations and a special exhibition for patient groups.

Marking, World Heart Day, held on 27 September 2009, the World Heart Federation, the World Health Organization and the World Economic Forum joined forces to call on governments, employers and workers around the world to make workplaces healthier.

Sanofi-aventis has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion recommending to grant a marketing authorization in the European Union for Multaq® (dronedarone – 400mg Tablets).

Professor Drexler was an active member of the European Society of Cardiology and sat on the board of the Heart Failure Association (HFA). Although Heart Failure was his main passion, Professor Drexler was also an important figure in stem-cell research. He was a principle investigator in the BOOST study and the CADS trial – a comparison of Captopril and Digoxin in patients with LV – dysfunction after myocardial infarction.